Tenax Therapeutics | SCHEDULE 13G/A: Others
Tenax Therapeutics | 3: Initial statement of beneficial ownership of securities-10% Owner Dellora Investments LP
Tenax Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Rich Stuart
Tenax Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director PROEHL GERALD T
Tenax Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hunter Robyn
Tenax Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Giordano Christopher Thomas
Tenax Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Doogan Declan
Tenax Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Davidson Michael H.
Tenax Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Almenoff June Sherie
Tenax Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer MCGAULEY THOMAS
Tenax Therapeutics | SCHEDULE 13G: Others
Tenax Therapeutics | 8-K: Current report
Tenax Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Tenax Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Lind Global Fund II LP(9.9%),Lind Global Partners II LLC(9.9%), etc.
Tenax Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Janus Henderson Group plc(10.0%),Janus Henderson Biotech Innovation Master Fund Ltd(10.0%)
Tenax Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-CVI Investments, Inc.(0%),Heights Capital Management, Inc.(0%)
Tenax Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Stonepine Capital Management, LLC(9.99%),Stonepine Capital, L.P(9.99%), etc.
Tenax Therapeutics | 10-Q: Q3 2024 Earnings Report
Tenax Therapeutics | 8-K: Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Tenax Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Adage Capital Management, L.P.(9.99%),Robert Atchinson(9.99%), etc.